Posted by Michael Wonder on 10 Feb 2025
ICER publishes evidence report on treatment for acute pain
5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic treatment, opioid analgesics, and NSAIDs; at expected pricing, treatment is likely to be cost effective in the long run.
The ICER today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of suzetrigine (Vertex Pharmaceuticals) for the treatment of acute pain.
